Following the set of largely established US and EU guidelines which recommend the decolonisation of patients’ noses of Staphylococcus aureus before surgery to prevent subsequent surgical site infections, Destiny recently reported the new Asia Pacific Society of Infection Control (APSIC) guidelines that are now harmonised with the US and EU positions. This is important for Destiny’s first product – XF-73 which is currently in a US Phase IIb study for the prevention of post-surgical staphylococcal infections.
18 Dec 2019
Differentiated anti-infectives
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Differentiated anti-infectives
Destiny Pharma Plc (DEST:LON) | 21.8 -0.1 (-1.1%) | Mkt Cap: 20.7m
- Published:
18 Dec 2019 -
Author:
Andy Smith -
Pages:
2
Following the set of largely established US and EU guidelines which recommend the decolonisation of patients’ noses of Staphylococcus aureus before surgery to prevent subsequent surgical site infections, Destiny recently reported the new Asia Pacific Society of Infection Control (APSIC) guidelines that are now harmonised with the US and EU positions. This is important for Destiny’s first product – XF-73 which is currently in a US Phase IIb study for the prevention of post-surgical staphylococcal infections.